The objective of this study is to evaluate the safety, tolerability as well as pharmacokinetics of Sudapyridine (WX-081) in Chinese volunteers.

In this study, a single-center, randomized, double-blind, placebo-controlled, dose-ascending design was used to evaluate the safety, tolerability and pharmacokinetic characteristics of Sudapyridine (WX-081) tablets in healthy Chinese subjects using placebo as control.

This study was divided into two stages. The first stage evaluated the tolerance of single administration, pharmacokinetic characteristics, and the effect of food on PK. The second stage evaluated the tolerance of multiple administration and PK characteristics.

Inclusion Criteria:

• Weight: ≥50 kg; 19≤ body mass index (BMI) < 26 kg/m2;
• Considered healthy by the investigator based on a detailed history, thorough physical examination, clinical laboratory examination, 12-lead ECG, and vital signs results;
• No parenting plan and reliable contraception during the trial period and within 3 months after the last dose.

Exclusion Criteria:

• Allergic to any drug of the same category or its ingredients;
• A history of alcohol dependence or drug abuse;
• Laboratory obvious abnormalities;
• CYP3A4 potent inducer or inhibitor had been taken within 30 days prior to enrollment;
• Any serious cardiovascular, kidney, liver, blood, tumor, endocrine and metabolic, autoimmune or rheumatic diseases.